Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis.
Transdermal Application of Myelin Peptides in Multiple Sclerosis Treatment.
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
Iran mass produces MS drug Ziferon
Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.
Individual oligodendrocytes have only a few hours in which to generate new myelin sheaths in vivo.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.
Gpr126 functions in Schwann cells to control differentiation and myelination via G-protein activation.
Clinical utility of the list sign as a predictor of non-demyelinating disorders in a multiple sclerosis (MS) practice.
Charcot-Marie-Tooth 1A: a narrative review with clinical and anatomical perspectives.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Chemotherapeutics in the treatment of multiple sclerosis.
Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis.
Are changes in gait and balance across the Disease Step Rating Scale in Multiple Sclerosis statistically significant and clinically meaningful?
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Data supporting the role of Fyn in initiating myelination in the peripheral nervous system.
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate.
Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b.
Testing the measurement invariance of the University of Washington Self-Efficacy Scale short form across four diagnostic subgroups.

Pages